NASDAQ:PGNY Progyny (PGNY) Stock Price, News & Analysis $28.97 -0.15 (-0.52%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$28.97 +0.00 (+0.01%) As of 10/23/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Progyny Stock (NASDAQ:PGNY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Progyny alerts:Sign Up Key Stats Today's Range$28.80▼$29.1150-Day Range$24.79▼$29.1252-Week Range$16.10▼$33.06Volume565,756 shsAverage Volume1.10 million shsMarket Capitalization$2.22 billionP/E Ratio31.49Dividend YieldN/APrice Target$34.36Consensus RatingModerate Buy Company Overview Progyny, Inc. is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers. Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process. Progyny primarily serves self-insured employers and their employees in the United States. The company was founded in 2015 and became a publicly traded company on the Nasdaq in 2019. Peter Anevski serves as chief executive officer, having previously held senior financial and operational roles at the company.AI Generated. May Contain Errors. Read More Progyny Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScorePGNY MarketRank™: 3.51307847082 of 5 starsProgyny scored higher than 70% of companies evaluated by MarketBeat, and ranked 208th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingProgyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 9 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialProgyny has a consensus price target of $34.36, representing about 18.6% upside from its current price of $28.97.Amount of Analyst CoverageProgyny has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Progyny's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth13.60% Earnings GrowthEarnings for Progyny are expected to grow by 13.60% in the coming year, from $1.25 to $1.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progyny is 31.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Progyny is 31.49, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.33.Price to Earnings Growth RatioProgyny has a PEG Ratio of 2.00. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioProgyny has a P/B Ratio of 4.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Progyny's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.36% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 4.09.Change versus previous monthShort interest in Progyny has recently increased by 8.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProgyny does not currently pay a dividend.Dividend GrowthProgyny does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.09 News SentimentProgyny has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Progyny this week, compared to 4 articles on an average week.Search Interest5 people have searched for PGNY on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $475,790.00 in company stock.Percentage Held by Insiders9.90% of the stock of Progyny is held by insiders.Percentage Held by Institutions94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Progyny's insider trading history. Receive PGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PGNY Stock News HeadlinesProgyny, Inc. Announces Details for Its Third Quarter 2026 Results ReportOctober 21, 2026 | globenewswire.comProgyny (PGNY) Gets a Buy from Wells FargoOctober 18, 2026 | theglobeandmail.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 25 at 1:00 AM | Banyan Hill Publishing (Ad)Progyny (NASDAQ:PGNY) COO Melissa Cummings Sells 1,879 Shares of StockOctober 17, 2026 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Progyny (PGNY)October 16, 2026 | theglobeandmail.comLeerink Partners Sticks to Its Buy Rating for Progyny (PGNY)October 16, 2026 | theglobeandmail.comProgyny to Present New Menopause Research at The Menopause Society 2026 Annual MeetingOctober 15, 2026 | globenewswire.comProgyny (NASDAQ:PGNY) EVP Sells 3,903 Shares of StockSeptember 29, 2026 | insidertrades.comSee More Headlines PGNY Stock Analysis - Frequently Asked Questions How have PGNY shares performed this year? Progyny's stock was trading at $25.68 at the start of the year. Since then, PGNY stock has increased by 12.8% and is now trading at $28.97. How were Progyny's earnings last quarter? Progyny, Inc. (NASDAQ:PGNY) issued its earnings results on Thursday, August, 6th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.33 by $0.22. The company's quarterly revenue was up 5.3% compared to the same quarter last year. Read the conference call transcript. Is Progyny doing a stock buyback? Progyny's board approved a stock buyback program on Tuesday, May 26th 2026, which allows the company to buy back $200,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 10.3% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's management believes its stock is undervalued. When did Progyny IPO? Progyny (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers. Who are Progyny's major shareholders? Progyny's top institutional investors include Fort Washington Investment Advisors Inc. OH (2.13%), Pinnacle Associates Ltd. (0.05%), Prime Capital Investment Advisors LLC (0.03%) and State of Alaska Department of Revenue (0.02%). Insiders that own company stock include Peter Anevski, Michael E Sturmer, David J Schlanger, Allison Swartz, Mark S Livingston, Melissa B Cummings, Geoffrey Clapp, Cheryl Scott and Kevin K Gordon. View institutional ownership trends. How do I buy shares of Progyny? Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Progyny own? Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Fortinet (FTNT), Tradeweb Markets (TW), Tesla (TSLA), NVIDIA (NVDA), Palantir Technologies (PLTR), Roku (ROKU) and Salesforce (CRM). Company Calendar Last Earnings8/06/2026Today10/25/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, PGNY's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:PGNY CIK1551306 Webwww.progyny.com Phone212-888-3124FaxN/AEmployees856Year Founded2008Price Target and Rating Average Price Target for Progyny$34.36 High Price Target$40.00 Low Price Target$30.00 Potential Upside/Downside+18.6%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$0.92 Trailing P/E Ratio31.49 Forward P/E Ratio23.18 P/E Growth2Net Income$58.52 million Net Margins6.00% Pretax Margin9.14% Return on Equity15.98% Return on Assets10.65% Debt Debt-to-Equity RatioN/A Current Ratio2.14 Quick Ratio2.14 Sales & Book Value Annual Sales$1.29 billion Price / Sales1.72 Cash Flow$0.74 per share Price / Cash Flow39.35 Book Value$5.99 per share Price / Book4.84Miscellaneous Outstanding Shares76,730,000Free Float69,131,000Market Cap$2.22 billion OptionableOptionable Beta1.02 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:PGNY) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.